US Patent

US11370755 — Compositions of trofinetide

Composition of Matter · Assigned to Neuren Pharmaceuticals Ltd New Zealand · Expires 2040-08-03 · 14y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compositions of trofinetide, including the molecule itself and pharmaceutical products containing it, for use in treating neurodegenerative or neurodevelopmental disorders.

USPTO Abstract

This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US11370755
Jurisdiction
US
Classification
Composition of Matter
Expires
2040-08-03
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Neuren Pharmaceuticals Ltd New Zealand
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.